報價延遲最少15分鐘:2025/01/21 05:21 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.93 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-10.25/-7.25
|
|
企業價值
10.77M
|
| 資產負債 |
|
每股賬面淨值
-23.90
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
53.47M
|
|
每股收益
22.97
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 05:21 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. |